CD138+ Plasma Cell Enrichment from Whole Blood and Bone Marrow

CD138 expression is a hallmark of plasma cells and multiple myeloma cells, and it is considered a useful marker in plasma cells tumors diagnostics. Using our newly developed MARS® CS system (multi-physics automated reconfigurable separation) we demonstrate a cost-efficient, fast and robust workflow for isolation of CD138+ cells from whole blood and bone marrow samples within a short […]

A New Approach for High Recovery and Purity Isolation of Plasma Cells from Whole Blood

Characterization of Plasma Cells in Bone Marrow for different cytogenetic abnormalities is a common genetic test to diagnose and monitor cell malignant disease such as multiple myeloma (MM). Plasma cells in MM patients varied in proportion from <1% up to 100%. For the less invasive sample collection, circulating plasma cells (CPCs) in peripheral blood have emerged as an important […]

Enhanced Rare Cell Sorting Capability Enabled by MARS and WOLF 

MARS acoustic technology utilizes active-microfluidics acoustics for the separation of sample particles without labeling, based only on the difference in their physical parameters. The isolated cells are ready for negative MARS MAG selection, where cells bound to magnetic beads are captured in flow channels, without the need for dedicated columns. Combining the two technologies, MARS enables […]

High purity and recovery Positive Selection of CD34+ cells from Whole Blood

CD34+ cell isolation from whole blood is usually performed with RBC lysis or a density gradient separation method, typically using Ficoll – based protocols. This methodology is very time and labor-intensive and leads to high cell loss. Our No-Lyse-No-Wash (NLNW) protocol is fast and cost-effective. The MARS Bar system together with MARS MAG LINE of […]

Rare Cancer Cell Isolation From Whole Blood Using the MARS Cell Separation System

Circulating tumor cells (CTCs) are cancer cells shed from tumors and circulate in the bloodstream. These cells are considered to be a biomarker which potentially has high value in cancer diagnosis and cancer drug development. However, because of the extremely low frequency of CTC in peripheral blood, which is typically as low as less than […]